Characteristics of patients with subchorionic hematomas in the second trimester

Yamada, Tetsuo; Atsuki, Yusuke; Wakasaya, Atsushi; Kobayashi, Mami; Hirano, Yuki; Ohwada, Michitaka

doi:10.1111/j.1447-0756.2011.01665.x

Cited by 12 publications

(14 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, its infectious frequency is believed to be around 10% on an average from a global perspective [1,2]. As compared to other studies with healthy women in Japan (~5.8% on average; 3.0-3.8% Tokyo [39,41]; 5.6% Fukuoka [42]; 8.3-8.8% Miyasaki [43,44]; 1.7% Nasushiobara [45]; 9.5% Wako [46]), the prevalence of C. trachomatis in Sapporo City that we estimated (14.3%) was unique. Our result is supported by a previous study showing a C. trachomatis detection frequency of 11.3% in Sapporo [47].…”

Section: Resultsmentioning

confidence: 99%

Frequency of Chlamydia trachomatis in Ureaplasma-positive healthy women attending their first prenatal visit in a community hospital in Sapporo, Japan

et al. 2012

View full text Add to dashboard Cite

Background Although Chlamydia trachomatis is the most commonly reported pathogen that causes urogenital infection such as urethritis or cervicitis, Ureaplasma parvum and Ureaplasma urealyticum , which are commensals in the genital tract, have also now been recognized as contributors to urogenital infection. However, whether the presence of either U. parvum or U. urealyticum is related to that of C. trachomatis in the urogenital tract remains unknown. We therefore attempted to estimate by PCR the prevalence of C. trachomatis, U. parvum and U. urealyticum in endocervical samples obtained from healthy women attending their first prenatal visit in Sapporo, Japan. Methods The samples were taken from 303 apparently healthy women, and the extracted DNAs ( n = 280) were used for PCR detection targeting C. trachomatis, U. parvum and U. urealyticum . Statistical analysis of the data was performed by Fisher's exact test. Results PCR detection revealed that the prevalence of C. trachomatis, U. parvum and U. urealyticum was 14.3% (40/280), 41.7% (117/280) and 8.9% (25/280), respectively. C. trachomatis ompA genotype D was most frequently identified. Surprisingly, either C. trachomatis or Ureaplasma spp. was detected in almost half of the healthy women. Mixed infection of C. trachomatis with either U. parvum or U. urealyticum was also observed in 9.2% (26/280) of the women. There was a significant association between C. trachomatis and either U. parvum ( p = 0.023) or Ureaplasma total ( p = 0.013), but not U. urealyticum ( p = 0.275). Conclusion This study demonstrated that the presence of Ureaplasma had a significant effect on the presence of C. trachomatis in the genital tract of healthy women, suggesting that mixed infection is an important factor in bacterial pathogenesis in the genital tract.

show abstract

Section: Resultsmentioning

confidence: 99%

Frequency of Chlamydia trachomatis in Ureaplasma-positive healthy women attending their first prenatal visit in a community hospital in Sapporo, Japan

et al. 2012

View full text Add to dashboard Cite

show abstract

“…Abnormalities in pregnancy, such as intrauterine bleeding or sub-chorionic hematomas are often associated with threatened miscarriage, especially during the first trimester of pregnancy. Sub-chorionic hematoma is a sonographically detected anechoic area with a falciform shape that increases the risk of spontaneous abortion [131]. Placental dysfunction, insufficient angiogenesis, and chronic inflammation are underlying causes of early pregnancy bleeding, and these factors can even result in preterm labor or perinatal mortality [132].…”

Section: α-Lipoic Acid In Clinical Trialsmentioning

confidence: 99%

Insights on the Use of α-Lipoic Acid for Therapeutic Purposes

et al. 2019

View full text Add to dashboard Cite

α-lipoic acid (ALA, thioctic acid) is an organosulfur component produced from plants, animals, and humans. It has various properties, among them great antioxidant potential and is widely used as a racemic drug for diabetic polyneuropathy-associated pain and paresthesia. Naturally, ALA is located in mitochondria, where it is used as a cofactor for pyruvate dehydrogenase (PDH) and α-ketoglutarate dehydrogenase complexes. Despite its various potentials, ALA therapeutic efficacy is relatively low due to its pharmacokinetic profile. Data suggests that ALA has a short half-life and bioavailability (about 30%) triggered by its hepatic degradation, reduced solubility as well as instability in the stomach. However, the use of various innovative formulations has greatly improved ALA bioavailability. The R enantiomer of ALA shows better pharmacokinetic parameters, including increased bioavailability as compared to its S enantiomer. Indeed, the use of amphiphilic matrices has capability to improve ALA bioavailability and intestinal absorption. Also, ALA’s liquid formulations are associated with greater plasma concentration and bioavailability as compared to its solidified dosage form. Thus, improved formulations can increase both ALA absorption and bioavailability, leading to a raise in therapeutic efficacy. Interestingly, ALA bioavailability will be dependent on age, while no difference has been found for gender. The present review aims to provide an updated on studies from preclinical to clinical trials assessing ALA’s usages in diabetic patients with neuropathy, obesity, central nervous system-related diseases and abnormalities in pregnancy.

show abstract

“…According to the literature, the incidence of SCH in the first trimester in a general obstetric population is 3.1% [4], the frequency of SCH in the group with threatened spontaneous miscarriages is 5.2% [1], and the frequency of SCH is significantly higher in the in vitro fertilization group (22.4%) [5]. Additionally, pregnant women with SCH in the first trimester show changes in vaginal flora in the second trimester, which suggests a possible association with subchorionic hematoma and vaginal flora change [6].…”

Section: Introductionmentioning

confidence: 99%

Pregnancy Outcomes in Pregnant Women with Subchorionic Hematoma

Буштырева¹,

Кузнецова²,

Barinova³

et al. 2015

Int J Biomed

View full text Add to dashboard Cite

Background: The role of subchorionic hematoma (SCH) in the first trimester of pregnancy remains open for discussion. Some authors claim that SCH does not affect the pregnancy; others have found that it is a serious risk factor for adverse pregnancy outcome. The objective of the present study was to explore the outcomes of pregnancy in patients with SCH diagnosed in the first trimester.Methods and Results: The study involved 194 pregnant women who were in terms of 6 to 12 weeks: 115 women with SCH (Group 1) and 79 apparently healthy pregnant women (Group 2). A missed miscarriage was observed in 27/23% women of Group 1 and in 4/5% of Group 2 (P<0.001), recurrent threat of miscarriage in 27/23% and in 4/5% (P<0.001), recurrent bleeding in 14/12% and 2/3% (P<0.02), and the short cervix syndrome in 22/19% and 5/6% (P<0.03) women, respectively. Conclusion:The results of our study show that the presence of SCH adversely affects the first half of pregnancy, leading to recurrent threatened abortion, recurrent threat of miscarriage, missed miscarriage until 12 weeks of gestation, and the short cervix syndrome. (Int I Biomed. 2015;5(3):137-140.)

show abstract

Characteristics of patients with subchorionic hematomas in the second trimester

Cited by 12 publications

References 23 publications

Frequency of Chlamydia trachomatis in Ureaplasma-positive healthy women attending their first prenatal visit in a community hospital in Sapporo, Japan

Frequency of Chlamydia trachomatis in Ureaplasma-positive healthy women attending their first prenatal visit in a community hospital in Sapporo, Japan

Insights on the Use of α-Lipoic Acid for Therapeutic Purposes

Pregnancy Outcomes in Pregnant Women with Subchorionic Hematoma

Contact Info

Product

Resources

About